ReviewCurrent diabetes reports2018
Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes.
Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04838561 (Assessing the Impact of Control-IQ Technology on Quality of Life and Glycemic Control in Children and Youth With Type 1 Diabetes in a Canadian Context), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing the Impact of Control-IQ Technology on Quality of Life and Glycemic Control in Children and Youth With Type 1 Diabetes in a Canadian Context
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges.Diabetes technology & therapeutics · 2022Trial
- Randomized Crossover Comparison of Automated Insulin Delivery Versus Conventional Therapy Using an Unlocked Smartphone with Scheduled Pasta and Rice Meal Challenges in the Outpatient Setting.Diabetes technology & therapeutics · 2020Trial
- Home Visits for Children and Adolescents with Uncontrolled Type 1 Diabetes.Diabetes technology & therapeutics · 2020Trial
- Insulin detection in diabetes mellitus: challenges and new prospects.Nature reviews. Endocrinology · 2023Review
- Clinical Evaluation of a Novel Insulin Immunosensor.Journal of diabetes science and technology · 2023Article
- Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1 Diabetes in a Real-World Setting.Pediatric diabetes · 2023Observational
- A review of biomarkers in the context of type 1 diabetes: Biological sensing for enhanced glucose control.Bioengineering & translational medicine · 2021Review
- Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology.Diabetes technology & therapeutics · 2021Article
- Development of an Error Model for a Factory-Calibrated Continuous Glucose Monitoring Sensor with 10-Day Lifetime.Sensors (Basel, Switzerland) · 2019Article
- Diabetic Gastroparesis.Endocrine reviews · 2019Review
- Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications.Diabetes & metabolism journal · 2019Review
- Adding wisdom to 'smart' bioelectronic systems: a design framework for physiologic control including practical examples.Bioelectronics in medicine · 2019Article
- Neuromodulation of metabolic functions: from pharmaceuticals to bioelectronics to biocircuits.Journal of biological engineering · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) RECENT
findingsThe Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.